Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism

Virology

Volumn 248, Issue 2, 1998, Pages 173-181

  Sullivan, Brenda L ^a   Takefman, Daniel M ^a   Spear, Gregory T ^a  

^a RUSH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5;

ARTICLE; COMPLEMENT ACTIVATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE COUNT; PRIORITY JOURNAL; VIREMIA; VIRUS INACTIVATION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS SHEDDING;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032168058     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9289     Document Type: Article

References (39)

1. Berberian L., Goodglick L., Kipps T. J., Braun J. Immunoglobulin VH3 gene products: Natural ligands for HIV gp120. Science. 261:1993;1588-1591.
2. Berberian L., Shukla J., Jefferis R., Braun J. Effects of HIV infection on VH3 (D12 idiotope) B cells in vivo. J. Acquir. Immune Defic. Syndr. 7:1994;641-646.
3. Coombs R. W., Henrard D. R., Mehaffey W. F., Gibson J., Eggert E., Quinn T. C., Phillips J. Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction. J. Clin. Microbiol. 31:1993;1980-1986.
4. Cooper N. R., Nemerow G. R. Complement, viruses, and virus-infected cells. Springer Semin. Immunopathol. 6:1983;327-347.
5. Cooper, N. R. Nemerow, G. R. 1986, Complement-dependent mechanisms of virus neutralization, In, Immunobiology of the Complement System, Academic Press, New York.
6. Dewar R. L., Highbarger H. C., Sarmiento M. D., Todd J. A., Vasudevachari M. B., Davey R. T. Jr., Kovacs J. A., Salzman N. P., Lane H. C., Urdea M. S. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J. Infect. Dis. 170:1994;1172-1179.
7. Ebenbichler C. F., Thielens N. M., Vornhagen R., Marschang P., Arlaud G. J., Dierich M. P. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J. Exp. Med. 174:1991;1417-1424.
8. Ezekowitz R. A., Kuhlman M., Groopman J. E., Byrn R. A. A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J. Exp. Med. 169:1989;185-196.
9. Finney, D. J. 1964, Statistical Method in Biological Assay, Griffin, London.
10. Gaudin M. C., Parren P. W., Weir R., Barbas C. F., Burton D. R., Koup R. A. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3:1997;1389-1393.
11. Gregersen J. P., Mehdi S., Baur A., Hilfenhaus J. Antibody- and complement-mediated lysis of HIV-infected cells and inhibition of viral replication. J. Med. Virol. 30:1990;287-293.
12. Haurum J. S., Thiel S., Jones I. M., Fischer P. B., Laursen S. B., Jensenius J. C. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS. 7:1993;1307-1313.
13. June R. A., Schade S. Z., Bankowski M. J., Kuhns M., McNamara A., Lint T. F., Landay A. L., Spear G. T. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS. 5:1991;269-274.
14. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
15. Li Y., Kappes J. C., Conway J. A., Price R. W., Shaw G. M., Hahn B. H. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: Identification of replication-competent and -defective viral genomes. J. Virol. 65:1991;3973-3985.
16. Mascola J. R., Louder M. K., VanCott T. C., Sapan C. V., Lambert J. S., Muenz L. R., Bunow B., Birx D. L., Robb M. L. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71:1997;7198-7206.
17. Mayer M. M., Hammer C. H., Michaels D. W., Shin M. L. Immunologically mediated membrane damage: The mechanism of complement action and the similarity of lymphocyte-mediated cytoxicity. Immunochemistry. 15:1978;813-831.
18. McKeating J. A., McKnight A., Moore J. P. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: Effects on infectivity and neutralization. J. Virol. 65:1991;852-860.
19. Montefiori D. C., Robinson W. E. Jr., Hirsch V. M., Modliszewski A., Mitchell W. M., Johnson P. R. Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J. Virol. 64:1990;113-119.
20. Montefiori D. C., Robinson W. E. Jr., Schuffman S. S., Mitchell W. M. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26:1988;231-235.
21. Moore J. P., Cao Y., Ho D. D., Koup R. A. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J. Virol. 68:1994;5142-5155.
22. Moore J. P., Ho D. D. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells. AIDS. 9:1995;S117-S136.
23. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1996;1582-1586.
24. Piatak M. Jr., Saag M. S., Yang L. C., Clark S. J., Kappes J. C., Luk K. C., Hahn B. H., Shaw G. M., Lifson J. D. Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction. AIDS. 7:1993a;S65-S71.
25. Piatak M. Jr., Saag M. S., Yang L. C., Clark S. J., Kappes J. C., Luk K. C., Hahn B. H., Shaw G. M., Lifson J. D. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 259:1993b;1749-1754.
26. Robert-Guroff M., Brown M., Gallo R. C. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature. 316:1985;72-74.
27. Robinson W. E. Jr., Montefiori D. C., Gillespie D. H., Mitchell W. M. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J. Acquir. Immune Defic. Syndr. 2:1989;33-42.
28. Robinson W. E. Jr., Montefiori D. C., Mitchell W. M. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet. 1:1988;790-794.
29. Saarloos M. N., Koenig R. E., Spear G. T. Elevated levels of iC3b and C4d, but not Bb, complement fragments from plasma of persons infected with human T cell leukemia virus (HTLV) with HTLV-I-associated myelopathy/tropical spastic paraparesis. J. Infect. Dis. 172:1995;1095-1097.
30. Senaldi G., Peakman M., McManus T., Davies E. T., Tee D. E., Vergani D. Activation of the complement system in human immunodeficiency virus infection: Relevance of the classical pathway to pathogenesis and disease severity. J. Infect. Dis. 162:1990;1227-1232.
31. Sissons J. G., Oldstone M. B. Antibody-mediated destruction of virus-infected cells. Adv. Immunol. 29:1980;209-260.
32. Spear G. T., Carlson J. R., Jennings M. B., Takefman D. M., Landay A. L. Complement-mediated, antibody-dependent neutralizing titers of sera from asymptomatic and symptomatic HIV-infected individuals. AIDS. 6:1992;1047.
33. Spear G. T., Landay A. L., Sullivan B. L., Dittel B., Lint T. F. Activation of complement on the surface of cells infected by human immunodeficiency virus. J. Immunol. 144:1990a;1490-1496.
34. Spear G. T., Sullivan B. L., Landay A. L., Lint T. F. Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J. Virol. 64:1990b;5869-5873.
35. Spear G. T., Takefman D. M., Sullivan B. L., Landay A. L., Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J. Virol. 67:1993;53-59.
36. Stoiber H., Ebenbichler C., Schneider R., Janatova J., Dierich M. P. Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1. AIDS. 9:1995;19-26.
37. Stoiber H., Thielens N. M., Ebenbichler C., Arlaud G. J., Dierich M. P. The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology. Eur. J. Immunol. 24:1994;294-300.
38. Sullivan B. L., Knopoff E. J., Saifuddin M., Takefman D. M., Saarloos M. N., Sha B. E., Spear G. T. Susceptibilityof HIV-1 plasma virus to complement-mediated lysis: Evidencefor a role in clearance of virus in vivo. J. Immunol. 157:1996;1791-1798.
39. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.